Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 21, Number 6—June 2015
Online Report

Consensus on the Development of Vaccines against Naturally Acquired Melioidosis

Direk LimmathurotsakulComments to Author , Simon G.P. Funnell, Alfredo G. Torres, Lisa A. Morici, Paul J. Brett, Susanna Dunachie, Timothy Atkins, Daniel M. Altmann, Gregory Bancroft, Sharon J. Peacock, and for The Steering Group on Melioidosis Vaccine Development
Author affiliations: Faculty of Tropical Medicine, Mahidol University, Thailand (D. Limmathurotsakul); Public Health England, London, United Kingdom (S.G.P. Funnell); University of Texas Medical Branch, Galveston, Texas, USA (A.G. Torres); Tulane University School of Medicine, New Orleans, Louisiana, USA (L.A. Morici); University of South Alabama, Mobile, Alabama, USA (P.J. Brett); University of Oxford, Oxford, United Kingdom (S. Dunnachie); Defence Science and Technology Laboratory, Porton Down, United Kingdom (T. Atkins); Imperial College, London (D. M. Altmann); London School of Hygiene and Tropical Medicine, London (G. Bancroft); University of Cambridge, Cambridge, United Kingdom (S.J. Peacock)

Main Article

Table

Comparison of potential usage and animal models required for development of vaccines against naturally acquired melioidosis versus melioidosis vaccines for biodefense purposes*

Vaccine characteristics Vaccines against naturally acquired melioidosis Melioidosis vaccines for biodefense purposes
Target population
Character Persons with diabetes mellitus Healthy persons
Route of exposure
 Skin inoculation
 Inhalation
Potential use of vaccine
Prophylaxis Yes Yes
Prophylaxis plus postexposure antimicrobial drug administration
 Yes*
 Yes†
Animal models
Addition of diabetic mouse model Required Not required
Route of Burkholderia pseudomallei challenge Subcutaneous Inhalation
Nonhuman primate model Required Required

*Administration of antimicrobial drugs after symptoms occur.
†Administration of antimicrobial drugs after release.

Main Article

1Group members are listed at the end of this article.

Page created: April 29, 2015
Page updated: April 29, 2015
Page reviewed: April 29, 2015
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external